KOSCO-II: Korean Stroke Cohort for Functioning and Rehabilitation-II

Sponsor
Samsung Medical Center (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04976894
Collaborator
(none)
2,431
1
132
18.4

Study Details

Study Description

Brief Summary

Korean Stroke Cohort for functioning and rehabilitation (KOSCO)-II is a large, multi-centre prospective cohort study for all acute first-ever stroke patients admitted to participating hospitals in nine distinct areas of Korea. This study is designed as a 10-year, longitudinal follow-up investigating the residual disabilities, activity limitations, and quality of life issues arising in patients suffering from first-ever stroke as previous similar stroke cohort with KOSCO. The main objectives of this study are to identify and compare the factors that influence residual disability and long-term quality of life in first-ever acute stroke patients with KOSCO. The secondary objectives of this study are to determine and compare the risk of mortality and recurrent vascular events in first-ever acute stroke patients with KOSCO. Investigators will investigate longitudinal health behaviors and patterns of healthcare utilization, including stroke rehabilitation care. Investigators will also investigate the long-term health status, mood, and quality of life in stroke patient caregivers. In addition, investigators will identify baseline and ongoing characteristics that are associated with secondary outcomes.

Condition or Disease Intervention/Treatment Phase
  • Other: open

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
2431 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Korean Stroke Cohort for Functioning and Rehabilitation-II
Actual Study Start Date :
Jan 1, 2020
Anticipated Primary Completion Date :
Dec 31, 2030
Anticipated Study Completion Date :
Dec 31, 2030

Outcome Measures

Primary Outcome Measures

  1. Change in Korean modified Barthel Index [3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months after stroke onset.]

    measurement for activities of daily living Minimum: 0, Maximum: 100 Higher scores means a better.

  2. Change in Euro Quality of Life-5 Dimensions measurement for quality of life [3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months after stroke onset.]

    measurement for quality of life Minimum: 0, Maximum: 1 Higher scores means a better.

  3. Change in Functional Independence Measurement [3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months after stroke onset.]

    measurement for activities of daily living Minimum: 0, Maximum: 126 Higher scores means a better.

  4. Change in Korean Mini-Mental State Examination [7 days, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months after stroke onset.]

    measurement for language function Minimum: 0, Maximum: 30 Higher scores means a better.

  5. Change in Korean Version of Frenchay Aphasia Screening Test [7 days, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months after stroke onset.]

    measurement for language function Minimum: 0, Maximum: 30 Higher scores means a better.

  6. Change in modified Rankin Scale [7 days, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months after stroke onset]

    Measurement for disability. Range of total score 0 to 6. 0 is no disability at all and 6 is death. Therefore, greater value means worse functional status

  7. Change in American Speech-Language-Hearing Association National Outcome Measurement System Swallowing Scale [7 days, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months after stroke onset]

    Measurement for swallowing function. Range of scale is 0 to 7, and greater value means better function. For example, 7 means no swallowing difficulty at all.

  8. Change in Geriatric depression scale-short form [3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months after stroke onset]

    measurement for depression. The scale is 0 to 15. 0 is normal whereas 15 indicates severe depression. Minimum: 0, Maximum: 15. Lower scores means a better.

  9. Change in Functional Ambulatory Category [7 days, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months after stroke onset]

    measurement for gait function Minimum: 0, Maximum: 5 Higher scores means a better.

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • First-ever acute stroke (ischemic stroke or intracerebral hemorrhage) with corresponding lesion and/or evidence of acute arterial occlusion on CT (A)- or MRI/A-scan.

  • Age ≥ 19 years at onset of stroke.

  • Onset of symptoms within seven days prior to inclusion.

Exclusion Criteria:
  • Transient ischemic attack.

  • History of stroke.

  • Traumatic intracerebral hemorrhage.

  • Not Korean.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Samsung Medical Center Seoul Korea, Republic of 135-710

Sponsors and Collaborators

  • Samsung Medical Center

Investigators

  • Principal Investigator: Yun-Hee Kim, MD.,PhD., Samsung Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yun-Hee Kim, Professor, Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT04976894
Other Study ID Numbers:
  • 2019-11-095
First Posted:
Jul 26, 2021
Last Update Posted:
Jul 28, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yun-Hee Kim, Professor, Samsung Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 28, 2021